Clinical Trial Update: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating camrelizumab plus famitinib malate in treatment-naïve PD-L1-positive recurrent or metastatic non-small cell lung cancer is in progress …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib malate (famitinib malate)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN